ライフサイエンスコーパス: fidarestat

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 were prevented in diabetic rats treated with fidarestat.

2 eatment with the aldose reductase inhibitor, fidarestat.

3 tely prevented in diabetic rats treated with fidarestat.

4 mmol/l glucose with or without 1 micro mol/l fidarestat.

5 Aldose reductase inhibition with fidarestat (16 mg . kg(-1) . d(-1)), administered to ob/

6 without the aldose reductase inhibitor (ARI) fidarestat (16 mg . kg(-1) . day(-1)) for 6 weeks starti

7 ow containing the aldose reductase inhibitor fidarestat (16 mg x kg(-1) x day (-1)) corrected all fun

8 t low or high dose of the AR inhibitor (ARI) fidarestat (2 or 16 mg. kg(-1). day(-1)).

9 the rats started receiving the AR inhibitor fidarestat (7 mg/kg/d; intraperitoneally).

10 Further, fidarestat also inhibits DOX-induced increase in troponi

11 was clear in diabetes, as was inhibition by fidarestat and by the p38 inhibitor SB 239063.

12 In BREC, fidarestat corrected hyperglycemia-induced increase in H

13 These results suggest that fidarestat could be used as adjuvant therapy to enhance

14 Fidarestat counteracted increased superoxide formation i

15 Fidarestat did not cause direct inhibition of PARP activ

16 Both low and high doses of fidarestat (i.e., the doses that partially and completel

17 re, we show that treatment of CRC cells with fidarestat increases the efficacy of DOX-induced death i

18 hat aldose reductase (AR) inhibitors such as fidarestat inhibit CRC growth in vitro and in vivo.

19 odies; and again, activation in diabetes and fidarestat inhibition was clear.

20 ings justify the rationale for evaluation of fidarestat on diabetic retinopathy.

21 inhibition by the pharmacological inhibitor fidarestat or ablation by AR-specific siRNA prevents hyp

22 ith a specific inhibitor of p38 (SB 239063), fidarestat, or insulin also prevented reductions in both

23 Fidarestat prevented the diabetes-induced increase in ni

24 reatment of HT29 cells with the AR inhibitor fidarestat significantly decreased the expression of vas

25 Treatment with fidarestat significantly prevented the EAU-induced ocula

26 ings reveal the new beneficial properties of fidarestat, thus further justifying the ongoing clinical

27 i in sciatic nerve, spinal cord, and DRGs of fidarestat-treated ob/ob mice did not differ from those

28 ay; ELISA) was dose-dependently prevented by fidarestat, whereas total VEGF mRNA and VEGF-164 mRNA (R

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。